Concurrent TSHR mutations and DIO2 T92A polymorphism result in abnormal thyroid hormone metabolism
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, Eunkuk | - |
dc.contributor.author | Jung, Jaehoon | - |
dc.contributor.author | Araki, Osamu | - |
dc.contributor.author | Tsunekawa, Katsuhiko | - |
dc.contributor.author | Park, So Young | - |
dc.contributor.author | Kim, Jeonghyun | - |
dc.contributor.author | Murakami, Masami | - |
dc.contributor.author | Jeong, Seon-Yong | - |
dc.contributor.author | Lee, Sihoon | - |
dc.date.available | 2020-02-27T10:40:52Z | - |
dc.date.created | 2020-02-07 | - |
dc.date.issued | 2018-07-04 | - |
dc.identifier.issn | 2045-2322 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/3555 | - |
dc.description.abstract | Deiodinase 2 (DIO2) plays an important role in thyroid hormone metabolism and its regulation. However, molecular mechanism that regulates DIO2 activity remains unclear; only mutaions in selenocysteine insertion sequence binding protein 2 and selenocysteine tranfer RNA (tRNA[Ser] Sec) are reported to result in decreased DIO2 activity. Two patients with clinical evidence of abnormal thyroid hormone metabolism were identified and found to have TSHR mutations as well as DIO2 T92A single nucleotide polymorphism (SNP). Primary-cultured fibroblasts from one patient present a high level of basal DIO2 enzymatic activity, possibly due to compensation by augmented DIO2 expression. However, this high enzymatic active state yet fails to respond to accelerating TSH. Consequently, TSHR mutations along with DIO2 T92A SNP ("double hit") may lead to a significant reduction in DIO2 activity stimulated by TSH, and thereby may have clinical relevance in a select population of hypothyroidism patients who might benefit from a T3/T4 combination therapy. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | NATURE PUBLISHING GROUP | - |
dc.relation.isPartOf | SCIENTIFIC REPORTS | - |
dc.subject | TYPE-2 IODOTHYRONINE DEIODINASE | - |
dc.subject | CONGENITAL HYPOTHYROIDISM | - |
dc.subject | COMBINATION THERAPY | - |
dc.subject | EXPRESSION | - |
dc.subject | THYROTROPIN | - |
dc.subject | GENE | - |
dc.subject | RECEPTOR | - |
dc.subject | THYROXINE | - |
dc.subject | TRIIODOTHYRONINE | - |
dc.subject | RESISTANCE | - |
dc.title | Concurrent TSHR mutations and DIO2 T92A polymorphism result in abnormal thyroid hormone metabolism | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000437249200017 | - |
dc.identifier.doi | 10.1038/s41598-018-28480-0 | - |
dc.identifier.bibliographicCitation | SCIENTIFIC REPORTS, v.8 | - |
dc.identifier.scopusid | 2-s2.0-85049624730 | - |
dc.citation.title | SCIENTIFIC REPORTS | - |
dc.citation.volume | 8 | - |
dc.contributor.affiliatedAuthor | Lee, Sihoon | - |
dc.type.docType | Article | - |
dc.subject.keywordPlus | TYPE-2 IODOTHYRONINE DEIODINASE | - |
dc.subject.keywordPlus | CONGENITAL HYPOTHYROIDISM | - |
dc.subject.keywordPlus | COMBINATION THERAPY | - |
dc.subject.keywordPlus | EXPRESSION | - |
dc.subject.keywordPlus | THYROTROPIN | - |
dc.subject.keywordPlus | GENE | - |
dc.subject.keywordPlus | RECEPTOR | - |
dc.subject.keywordPlus | THYROXINE | - |
dc.subject.keywordPlus | TRIIODOTHYRONINE | - |
dc.subject.keywordPlus | RESISTANCE | - |
dc.relation.journalResearchArea | Science & Technology - Other Topics | - |
dc.relation.journalWebOfScienceCategory | Multidisciplinary Sciences | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.